Agency / Source: Bharat Biotech International Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

First Indian Vaccine Manufacturer to Successfully Produce Revac-Bmcf - A Thimerosal-free Hepatitis-B - A thimerosal -free hepatitis vaccine is preferred choice of pediatricians for birth dose vaccination of new born babies within 12 hours of birth
First Indian Vaccine Manufacturer to Successfully Produce Revac-Bmcf - A Thimerosal-free Hepatitis-B

 

PRZOOM - /newswire/ - Hyderabad, Andhra Pradesh, India, 2007/10/30 - A thimerosal -free hepatitis vaccine is preferred choice of pediatricians for birth dose vaccination of new born babies within 12 hours of birth.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bharat Biotech once again becomes the first Indian vaccine manufacturer to successfully produce Revac-Bmcf, a thimerosal -free Hepatitis B Vaccine and usher in an era of preferred vaccines. A thimerosal -free hepatitis vaccine is preferred choice of pediatricians for birth dose vaccination of new born babies within 12 hours of birth. The launch of Revac-Bmcf (thimerosal -free) at an affordable price by Bharat Biotech will also address the needs of parents and members of the medical fraternity who prefer the use of thimerosal -free vaccines.

Globally, Seven multinational companies (MNC’s) manufacture thimerosal -free vaccines such as Hepatitis B, Flu, Hepatitis A, DTaP, DTap+HepB+IPV, Hib, Hib+Hep B, HPV, IPV, MMR, MMR+Varicella, Pneumococcal, Rabies, Typhoid and Yellow Fever vaccines for use in markets worldwide. Bharat Biotech joins this elite club of vaccine manufacturers in developing, manufacturing and commercializing thimerosal -free vaccines. Several other vaccines in the current product line and future pipeline of Bharat Biotech will also be developed and commercialized in thimerosal -free presentations.

Bharat Biotech has a successful track record of manufacturing a Thimerosal -free pediatric vaccine for a highly reputed MNC on a contract basis for overseas regulated markets. Having succeeded as the first Indian vaccine manufacturer to eliminate the use of Cesium chloride in Hepatitis B Vaccines, Bharat Biotech is forging ahead with a current portfolio of 10 injectable sterile preparations including 7 vaccines.

Bharat Biotech has effectively optimized its production technologies to ensure the phasing out of thimerosal as a preservative wherever possible.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bharat Biotech International Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


First Indian Vaccine Manufacturer to Successfully Produce Revac-Bmcf - A Thimerosal-free Hepatitis-B

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dr Krishna Mohan - BharatBiotech.com 
+91 40 23480567 mohank[.]bharatbiotech.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bharat Biotech International Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Bharat Biotech International Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today